TP53 and endometrial carcinoma: More specifically, using immunohistochemistry (p53, MSH6, PMS2) and polymerase epsilon (POLE) mutation testing, ECs can be divided into four biologically distinct groups: POLE-mutated (POLEmut), mismatch repair deficiency (MMRd), p53-abnormal (p53abn), and no specific molecular profile (NSMP) and finally categorized into four prognostic risk groups as low-, intermediate-, intermediate/high, and high-risk, with only 5% of endometrial carcinomas, termed “multiple classifiers”, exhibiting overlapping molecular features.